Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
By Eric Topor
A decision against Kmart Corp. for allegedly misreporting retail drug prices won’t be reviewed by the Supreme Court, leaving in place a whistle-blower victory ( Kmart Corp. v. United States ex rel. Garbe , U.S., No. 16-408, review denied 1/9/17 ).
The Supreme Court declined to wade into False Claims Act arguments over whether pharmacies have to report discounts given to retail customers to the government as the usual and customary prices of drugs. The usual and customary prices are generally what a retail customer pays out-of-pocket for a particular drug and are used by the government for Medicare and Medicaid drug pricing.
The U.S. Court of Appeals for the Seventh Circuit ruled in May 2016 that retail price discounts or club discounts given to Kmart pharmacy customers paying out-of-pocket should have been included in Kmart’s usual and customary drug price reports. The appeals court also said 2009 FCA amendments widening FCA liability applied retroactively to pre-amendment claims for payment made by pharmacies and providers as well.
The Supreme Court’s decision Jan. 9 not to review the appeals court’s decision means that both of those holdings will remain undisturbed. The Seventh Circuit’s decision affirmed the district court’s ruling denying Kmart summary judgment, and the case is proceeding through pretrial discovery. Trial is scheduled to begin Aug. 14 unless a settlement is reached.
Whistle-blowers have had recent litigation successes alleging FCA violations through retail pharmacy discount programs, and the Seventh Circuit’s decision has formed the basis of a recent whistle-blower win against Safeway Inc. A federal district court in Illinois declined Nov. 30 to dismiss a pharmacist whistle-blower’s allegations against Safeway for fraudulently reporting high out-of-pocket drug prices by omitting discounts. It specifically cited the Seventh Circuit’s Garbe ruling as controlling precedent.
National grocer SuperValu Inc. is facing similar whistle-blower charges against its retail pharmacy operations as well. A federal district court in Illinois rejected SuperValu’s motion to dismiss the FCA allegations brought by whistle-blowers Tracy Schutte and Michael Yarberry Oct. 21, and litigation is ongoing.
In addition, a federal district court in Indiana declined to dismiss similar allegations against Houchens Industries Inc.'s discount drug program at its Hometown IGA pharmacy locations in a case settled in in July 2015, and Texas grocery chain H-E-B settled similar allegations against its discount drug program for $12 million in 2014.
A spokesman for Kmart’s parent corporation, Sears Holding Corp., declined to comment on the Supreme Court’s decision to reject Kmart’s petition for review. Counsel for whistle-blower James Garbe didn’t respond to Bloomberg BNA’s request for comment.
King & Spalding LLP represented Kmart. Korein Tillery LLC represented Garbe.
To contact the reporter on this story: Eric Topor in Washington at email@example.com
To contact the editor responsible for this story: Peyton Sturges at firstname.lastname@example.org
The Seventh Circuit's decision is at http://src.bna.com/fr6.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)